Then, we further demonstrated that the METCAM/MUC18 concentrations were elevated in the serum of the prostate cancer patients, suggesting that the elevated serum METCAM/MUC18 concentrations may be used for predicting the malignant potential of prostate cancer and at least complement the PSA test [18]. This evidence concerns the gene MCAM and prostate carcinoma.